Immune Design Corp. (IMDZ) Analysts See $-0.30 EPS

July 27, 2018 - By Margaret Guttierez

Investors sentiment decreased to 1.57 in 2018 Q1. Its down 0.35, from 1.92 in 2017Q4. It is negative, as 11 investors sold Immune Design Corp. shares while 12 reduced holdings. 10 funds opened positions while 26 raised stakes. 21.61 million shares or 6.41% less from 23.09 million shares in 2017Q4 were reported.
Ecor1 Capital Limited Liability stated it has 1.45% in Immune Design Corp. (NASDAQ:IMDZ). Focused Wealth Inc owns 12,395 shares. Credit Suisse Ag owns 0% invested in Immune Design Corp. (NASDAQ:IMDZ) for 12,152 shares. Weiss Multi has 80,000 shares. Dimensional Fund Advsrs Ltd Partnership has 0% invested in Immune Design Corp. (NASDAQ:IMDZ) for 192,330 shares. State Of Wisconsin Investment Board reported 12,000 shares or 0% of all its holdings. Guggenheim Capital Ltd Llc holds 11,306 shares or 0% of its portfolio. California State Teachers Retirement System, California-based fund reported 50,518 shares. Goldman Sachs Grp holds 18,722 shares. Intl has 20,486 shares. Personal Cap Corporation invested in 24,000 shares or 0% of the stock. Meeder Asset Management holds 387 shares. Northern Trust Corporation holds 0% or 322,441 shares. Bnp Paribas Arbitrage invested in 6,113 shares. State Street Corporation accumulated 392,833 shares.

Analysts expect Immune Design Corp. (NASDAQ:IMDZ) to report $-0.30 EPS on August, 1.They anticipate $0.24 EPS change or 44.44 % from last quarter’s $-0.54 EPS. After having $-0.28 EPS previously, Immune Design Corp.’s analysts see 7.14 % EPS growth. The stock increased 1.23% or $0.05 during the last trading session, reaching $4.1. About 127,113 shares traded. Immune Design Corp. (NASDAQ:IMDZ) has declined 47.53% since July 27, 2017 and is downtrending. It has underperformed by 60.10% the S&P500.

Immune Design Corp., a clinical-stage immunotherapy company, engages in the research and development of in vivo treatments for cancer. The company has market cap of $197.31 million. It primarily develops oncology product candidates based on its ZVex and GLAAS product discovery platforms. It currently has negative earnings. The company's products include CMB305, which is in Phase 2 trial for the treatment of NY-ESO-1 tumor antigen; LV305 that is in Phase 1 trial for the treatment of patients with relapsed or metastatic melanoma, sarcoma, ovarian cancer, or non-small cell lung cancer that express NY-ESO-1; and G100, an intratumoral immune activation product candidate for the treatment of patients with Merkel cell carcinoma and non-Hodgkin Lymphoma.

Another recent and important Immune Design Corp. (NASDAQ:IMDZ) news was published by Nasdaq.com which published an article titled: “Immune Design to Report Second Quarter 2018 Financial Results and Provide Corporate Update” on July 25, 2018.

Immune Design Corp. (NASDAQ:IMDZ) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.